Related Experiment Videos
Strategies for Increasing Pancreatic Tumor Immunogenicity
Burles A Johnson1, Mark Yarchoan1, Valerie Lee1
1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland.
Summary
Immunotherapy is ineffective for pancreatic cancer due to its immunosuppressive microenvironment. Combination therapies targeting multiple signals show promise for improving outcomes in pancreatic ductal adenocarcinoma (PDAC).
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Immunotherapy has revolutionized cancer treatment for several deadly cancers.
- However, single-agent immunotherapy has shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC).
- The PDAC microenvironment creates an immunosuppressive milieu resistant to immunotherapy.
Purpose of the Study:
- To review the differences between immunotherapy-sensitive cancers and PDAC.
- To explore the complex interactions within the PDAC microenvironment.
- To identify druggable immunologic targets and evaluate combination therapy approaches for PDAC.
Main Methods:
- Review of existing literature on immunotherapy, PDAC, and the tumor microenvironment.
- Analysis of cellular and stromal interactions in PDAC.
- Evaluation of preclinical and clinical data for combination drug strategies.
Main Results:
- PDAC exhibits unique characteristics contributing to its resistance to immunotherapy.
- The interplay between PDAC cells, immune cells, and stroma creates a highly immunosuppressive environment.
- Specific immunologic targets within this network are identifiable and druggable.
Conclusions:
- Combination therapies modulating multiple signals in the PDAC microenvironment are crucial for clinical success.
- Targeting the complex PDAC stroma and immune cell interactions is essential.
- Future strategies should focus on combination approaches to overcome immunotherapy resistance in PDAC.